The 22 most recent market catalysts affecting $IONS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 75
Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease
Ionis Pharmaceuticals and its partner Roche announced positive interim results from their Phase 3 IMAgINATION trial for sefaxersen, a novel RNA-targeted therapy for IgA nephropathy…
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 85
Ionis Pharmaceuticals And Partner Roche Said Prespecified Interim Results From Phase 3 IMAgINATION Study Of Sefaxersen For Primary IgA Nephropathy Met Its Primary Endpoint Of Statistically Significant And Clinically Meaningful Improvements In Proteinuria Reduction Vs. Placebo At 37 Weeks
Ionis Pharmaceuticals, in partnership with Roche, announced that their drug candidate sefaxersen met its primary endpoint in a Phase 3 interim analysis for IgA Nephropathy (IgAN). …
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 85
Ionis to Seek Expedited FDA Review for ALS Drug
Ionis Pharmaceuticals (IONS) announced highly positive topline results from its Phase 3 FUSION trial for ulefnersen, an investigational drug for FUS-ALS. The drug met its primary e…
Sep 22, 2026
Corporate Catalyst
Bearish
Impact 55
JP Morgan Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $70
JP Morgan analyst Jessica Fye has maintained an 'Overweight' rating on Ionis Pharmaceuticals (IONS) but lowered the price target from $76 to $70. This adjustment suggests that whil…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 95
Ionis Pharmaceuticals shares are trading higher after the company and Otsuka said the Phase 3 FUSION study of ulefnersen met its primary endpoint.
The successful Phase 3 trial for ulefnersen is a significant de-risking event for Ionis Pharmaceuticals, directly impacting its future revenue potential and stock valuation. Positi…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 85
Ionis Pharmaceuticals And Otsuka Say Ulefnersen Meets Primary Endpoint In Phase 3 FUSION Trial In FUS-ALS
The successful Phase 3 trial for Ulefnersen in FUS-ALS is a major positive catalyst for Ionis Pharmaceuticals and its partner Otsuka. Meeting the primary endpoint significantly inc…
Sep 15, 2026
Corporate Catalyst
Bearish
Impact 75
Ionis Pharmaceuticals shares are trading lower after Guggenheim lowered its price target on the stock from $89 to $80.
This headline represents a significant corporate catalyst for Ionis Pharmaceuticals. Analyst downgrades, especially from prominent firms like Guggenheim, often trigger immediate ne…
Sep 9, 2026
Corporate Catalyst
Bearish
Impact 55
Barclays Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $85
Barclays analyst Eliana Merle maintained an 'Overweight' rating on Ionis Pharmaceuticals (IONS) but lowered the price target from $90 to $85. This action signals a slight reduction…
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 55
Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $104
Morgan Stanley analyst Michael Ulz reiterated an 'Overweight' rating on Ionis Pharmaceuticals, signaling continued confidence in the company's long-term prospects. However, the sim…
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 55
Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $56
Goldman Sachs analyst Salveen Richter maintained a 'Neutral' rating on Ionis Pharmaceuticals but reduced the price target from $69 to $56. This action signals a more cautious outlo…
Sep 4, 2026
Corporate Catalyst
Neutral
Impact 55
Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $86 Price Target
Needham analyst Joseph Stringer reiterated a 'Buy' rating and maintained an $86 price target for Ionis Pharmaceuticals. This action signals that the analyst's fundamental outlook o…
Sep 4, 2026
Corporate Catalyst
Neutral
Impact 75
Ionis Pharmaceuticals Exec Says Zanvastro Will Be Available At List Price Of $285K Per Dose
Ionis Pharmaceuticals disclosed the list price for its recently FDA-approved drug, Zanvastro (zilgeseran), at $285,000 per dose. This is a crucial piece of information following a …
Sep 4, 2026
Corporate Catalyst
Bullish
Impact 85
Ionis Drug Wins FDA Approval as First Alexander Disease Treatment
Ionis Pharmaceuticals (IONS) announced FDA approval for Zanvastro, its drug for Alexander disease. This is a major positive catalyst as Zanvastro is the first and only disease-modi…
Sep 4, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $115 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterated a 'Buy' rating and maintained a $115 price target for Ionis Pharmaceuticals. This action signals continued analyst confide…
Aug 19, 2026
Corporate Catalyst
Neutral
Impact 55
BMO Capital Initiates Coverage On Ionis Pharmaceuticals with Market Perform Rating, Announces Price Target of $60
BMO Capital's initiation of coverage on Ionis Pharmaceuticals (IONS) with a 'Market Perform' rating and a $60 price target provides a new data point for investors. While not a 'buy…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $76
JP Morgan analyst Jessica Fye has maintained an 'Overweight' rating on Ionis Pharmaceuticals and raised the price target from $72 to $76. This action signals continued confidence f…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 55
Wells Fargo Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $95
Wells Fargo analyst Yanan Zhu maintained an 'Overweight' rating on Ionis Pharmaceuticals, signaling continued confidence in the company's long-term prospects. However, the price ta…
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 55
Ionis Pharmaceuticals Affirms FY2026 Sales Guidance of $875.000M-$900.000M vs $895.148M Est
Ionis Pharmaceuticals filed an 8-K to affirm its FY2026 sales guidance, keeping the range at $875 million to $900 million. This is significant because it shows consistency in the c…
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 92
Ionis Pharmaceuticals Q2 Adj. EPS $(0.42) Beats $(1.07) Estimate, Sales $268.000M Beat $190.670M Estimate
Ionis Pharmaceuticals announced its Q2 earnings, revealing an adjusted EPS of $(0.42) and sales of $268.000 million. Both figures surpassed analyst consensus estimates of $(1.07) a…
Jul 13, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $85
RBC Capital's analyst Luca Issi reaffirmed an 'Outperform' rating for Ionis Pharmaceuticals but reduced the price target from $100 to $85. This action signals that while the analys…
Jul 13, 2026
Corporate Catalyst
Neutral
Impact 65
Ionis Pharmaceuticals Doses First Participant In Phase 1-2 ASCEND Study Of Ion337 For Dravet Syndrome, A Neurological Disorder
Ionis Pharmaceuticals has initiated its Phase 1-2 ASCEND study for ION337, a drug targeting Dravet syndrome, by dosing the first participant. This is a positive development for Ion…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.